Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
169
天
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study
作者
Michael Pavlides; Yasaman Vali; Ferenc E. Mózes; Kristy Wonders; Salma Akhtar; Paul D. Hockings; Elizabeth Shumbayawonda; Kay Pepin; Isabel Fernandez-Lizaranzu; Diana Julie Leeming; Jeremy F. Cobbold; Michael E. D. Allison; Guruprasad P. Aithal; Manuel Romero-Gomez; Rocio Aller; Juan M. Pericàs; Jérôme Boursier; Salvatore Petta; Jörn M. Schattenberg; Mattias Ekstedt; Annalisa Berzigotti; Hannele Yki-Järvinen; Miljen Martic; Theresa Tuthill; Clifford A. Brass; Michael Kalutkiewicz; Rajarshi Banerjee; Richard L. Ehman; Moritz J. Schneider; Dina Tiniakos; Morten Karsdal; Jeremy Magnanensi; Céline Fournier-Poizat; Vlad Ratziu; Carla Yunis; Elisabetta Bugianesi; Stephen A. Harrison; Patrick M. Bossuyt; Quentin M. Anstee展开收起
作者单位
1. Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; 2. Translational Gastroenterology and Liver Unit, University of Oxford, Oxford, UK; 3. Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust and the University of Oxford, Oxford, UK; 4. Department of Epidemiology and Data Science, Amsterdam Public Health, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; 5. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 6. Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; 7. Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 8. Antaros Medical AB, Mölndal, Sweden; 9. Perspectum Ltd., Oxford, UK; 10. Resoundant Inc., Rochester, USA; 11. Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain; 12. Hepatic and Digestive Diseases Networking Biomedical Research Centre (CIBERehd), Grupo de Física Interdisciplinar, Universidad de Sevilla, Sevilla, Spain; 13. Nordic Bioscience, Biomarkers & Research, Herlev, Denmark; 14. Liver Unit, Department of Medicine, Cambridge NIHR Biomedical Research Centre, Cambridge University NHS Foundation Trust, Cambridge, UK; 15. NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK; 16. Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK; 17. Digestive Diseases Unit, Hospital Universitario Virgen del Rocío, Sevilla, Spain; 18. Hepatic and Digestive Diseases Networking Biomedical Research Centre (CIBERehd), Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain; 19. Department of Gastroenterology, Clinic University Hospital, Medical School, University of Valladolid, CIBERINFEC, Valladolid, Spain; 20. Liver Unit, Vall d’Hebron Institut de Recerca, Vall d’Hebron Barcelona Hospital, Universitat Autònoma de Barcelona, Centros de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; 21. HIFIH Laboratory, SFR ICAT 4208, Angers University, Angers, France; 22. Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France; 23. Section of Gastroenterology and Hepatology, PROMISE, Palermo, Italy; 24. Department of Internal Medicine II, Saarland University Medical Center, Homburg, Germany; 25. Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden; 26. Department for Visceral Medicine and Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; 27. Department of Biomedical Research, University of Bern, Bern, Switzerland; 28. Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; 29. Minerva Foundation Institute for Medical Research, Helsinki, Finland; 30. Novartis Institutes for BioMedical Research, Basel, Switzerland; 31. Digital Sciences and Translational Imaging, Pfizer Inc., Cambridge, USA; 32. Resolution Therapeutics, London, UK; 33. Department of Radiology, Mayo Clinic, Rochester, USA; 34. Department of Pathology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; 35. Genfit S.A., Loos, France; 36. Echosens, Paris, France; 37. ICAN Institute for Cardiometabolism and Nutrition, INSERM UMRS 1138 CRC, Sorbonne Université, Paris, France; 38. Assistance-Publique Hôpitaux de Paris, INSERM UMRS 1138 CRC, Paris, France; 39. Research and Development, Pfizer Inc., Lake Mary, USA; 40. Department of Medical Sciences, University of Turin, Torino, Italy展开收起
25
天
Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials
作者
Martina L. Porter; Antonio Martorell; Christopher J. Sayed; Falk G. Bechara; Hadar Lev-Tov; Jennifer L. Hsiao; John W. Frew; Ziad Reguiaï; Melinda J. Gooderham; Noah Goldfarb; Hessel H. van der Zee; Veronique del Marmol; Angelo V. Marzano; Benjamin D. Ehst; Lindsay S. Ackerman; Koremasa Hayama; Chenwei Tian; Jennifer Kelley; Huiling Zhen; Joslyn S. Kirby; Kurt Brown; Leandro L. Santos; Christos C. Zouboulis展开收起
作者单位
1. Department of Dermatology, Harvard Medical School, Boston, USA; 2. Beth Israel Deaconess Medical Center, Boston, USA; 3. Inflammatory Diseases Unit, Department of Dermatology, Venereology and Surgery, Hospital de Manises, Valencia, Spain; 4. Department of Dermatology, University of North Carolina School of Medicine, Chapel Hill, USA; 5. ICH – International Center for Hidradenitis Suppurativa/Acne Inversa, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany; 6. Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, USA; 7. Department of Dermatology, University of Southern California, Los Angeles, USA; 8. Laboratory of Translational Cutaneous Medicine, Ingham Institute for Applied Medical Research, Liverpool, Australia; 9. Department of Dermatology, Liverpool Hospital, Liverpool, Australia; 10. School of Clinical Medicine, University of New South Wales Sydney, Kensington, Australia; 11. Department of Dermatology, Polyclinique Courlancy-Bezannes, Reims-Bezannes, France; 12. Probity Medical Research, Waterloo, Canada; 13. SKiN Centre for Dermatology, Peterborough, Canada; 14. Queen’s University, Kingston, Canada; 15. Departments of Dermatology and Medicine, University of Minnesota, Minneapolis, USA; 16. Department of Dermatology, University of Minnesota Physicians, Minneapolis, USA; 17. Department of Dermatology, Erasmus Medical Center, Rotterdam, Netherlands; 18. Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; 19. Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; 20. Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy; 21. Oregon Medical Research Center, Portland, USA; 22. USA Medical Dermatology Specialists, US Dermatology Partners, Phoenix, USA; 23. Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Itabashi City, Tokyo, Japan; 24. Incyte Corporation, Wilmington, USA; 25. Department of Dermatology, Venereology, and Immunology, Universitaetsklinikum Ruppin-Brandenburg, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Neuruppin, Germany展开收起
255
天
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
作者
Adam D. Cohen; Joshua Richter; Suzanne Trudel; Alexander Lesokhin; Jacob P. Laubach; Sheeba K. Thomas; Simon J. Harrison; Luciano J. Costa; Andrew Spencer; Rafael Fonseca; Peter A. Forsberg; Jesus G. Berdeja; Rayan Kaedbey; Nizar J. Bahlis; Paula Rodriguez-Otero; Maria-Victoria Mateos; Tulika Tyagi; Divya Samineni; Wenyu Liu; Rin Nakamura; Voleak Choeurng; Chihunt Wong; James Cooper; Amrita Krishnan展开收起
作者单位
1. Abramson Cancer Center and University of Pennsylvania, Philadelphia, USA; 2. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; 3. Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada; 4. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA; 5. Dana-Farber Cancer Institute, Boston, USA; 6. The University of Texas MD Anderson Cancer Center, Houston, USA; 7. Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, Australia; 8. O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, USA; 9. Alfred Health-Monash University, Melbourne, Australia; 10. Mayo Clinic in Arizona, Phoenix, USA; 11. University of Colorado School of Medicine, Aurora, USA; 12. Tennessee Oncology and Sarah Cannon Research Institute, Nashville, USA; 13. Jewish General Hospital, McGill University, Montreal, Canada; 14. Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada; 15. Clínica Universidad de Navarra, Pamplona, Spain; 16. Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (CIC) and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain; 17. Genentech, Inc., South San Francisco, USA; 18. City of Hope Duarte, Duarte, USA展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天